Yescarta denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta as Experimental

Yescarta (axicabtagene ciloleucel) received FDA approval for specified relapsed or refractory hematologic malignancies. An "experimental" denial from UHC — also sometimes labeled "investigational" or "not medically necessary due to lack of proven efficacy" — is inconsistent with FDA approval for an on-label indication. This type of denial most commonly results from one of the following: the requested indication is slightly outside Yescarta's exact approved label, UHC's internal medical policy has not been updated to reflect a newer FDA approval, or the claim was coded in a way that suggests an off-label use.

## Why This Is Appealable

FDA approval is the foundational standard for distinguishing experimental from established therapy. When a treatment is FDA-approved for the indication being treated, an "experimental" denial is on weak legal and clinical footing. Multiple courts and external reviewers have overturned such denials when the prescriber clearly documents the on-label indication. If the use is genuinely off-label, major oncology guidelines (such as those from NCCN) may still support coverage; UHC's own policies often allow coverage for treatments listed in recognized compendia.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the timeframe shown on your denial notice. Expedited internal appeal (72-hour decision) is strongly recommended given the nature of the diagnosis.
• External review: After exhausting the internal appeal, request IRO review within the four-month external review window. For oncology cases involving life-threatening conditions, expedited external review is almost always available.

## Documentation to Collect

1. FDA approval documentation — print or link the current FDA label for Yescarta, highlighting the approved indication that applies to your diagnosis. 2. Diagnosis and staging records — pathology, flow cytometry, imaging, and any molecular or genomic testing confirming the diagnosis that falls within the FDA-approved indication. 3. Prior lines of therapy — document every prior treatment with dates and outcomes, confirming your relapsed/refractory status as required by the label. 4. Oncologist letter — should state explicitly that Yescarta is FDA-approved for your diagnosis as documented, reference the relevant section of the prescribing label, and note guideline support from the applicable oncology guideline organization. 5. UHC's own policy — obtain their current CAR-T / Yescarta medical policy and confirm whether FDA-approved indications are covered; highlight any language that contradicts the denial.

## Criteria-Mapping Structure

Side-by-side table: left column lists UHC's stated reasons for the experimental determination; right column provides the FDA label language, the diagnosis documentation, and the prior-therapy history that refutes each reason. Attach the FDA label as a labeled exhibit.